Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
113 hedge funds and large institutions have $285M invested in Jounce Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 34 increasing their positions, 41 reducing their positions, and 20 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
5% less call options, than puts
Call options by funds: $390K | Put options by funds: $410K
9% less funds holding
Funds holding: 124 → 113 (-11)
17% less capital invested
Capital invested by funds: $343M → $285M (-$57.3M)
17% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 41
50% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$13M |
| 2 |
Morgan Stanley
New York
|
+$10.6M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$8.92M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$4.89M |
| 5 |
CAC
Cowen and Company
New York
|
+$4.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$11.4M |
| 2 |
TGI
TRV GP II
Boston,
Massachusetts
|
-$9.62M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.82M |
| 4 |
Goldman Sachs
New York
|
-$2.34M |
| 5 |
Barclays
London,
United Kingdom
|
-$1.84M |
JNCE Hedge Fund Activity: Q1 2022 in Review
113 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q1 2022, worth a combined $285M — down 17% from $343M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of JNCE and 10 opened new positions — a net loss of 10 holders — while 41 trimmed existing stakes and 34 added.
The largest buyer was RTW Investments, adding an estimated $13M. The largest seller was Woodline Partners, exiting entirely with an estimated $11.4M sold.
- 113 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q1 2022, down from 124 in Q4 2021.
- Funds reported $285M of Jounce Therapeutics, Inc. Common Stock stock for Q1 2022, down 17% quarter-over-quarter.
- 10 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q1 2022 and 20 closed out, a net change of -10 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q1 2022 was RTW Investments, an estimated $13M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q1 2022 was Woodline Partners, an estimated $11.4M sold.
Based on aggregated 13F filings for Q1 2022.